“The launch of SEZABY is an exciting addition to our growing portfolio of specialty branded products in the US,” Sun Pharma CEO North America Abhay Gandhi said. He further said, “As the first and only FDA-approved product for the treatment of seizures in term and preterm infants, SEZABY has the potential to make a meaningful difference in the lives of patients and their families, and we are proud to be able to provide physicians with this new treatment option.”
